To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?-Reference-Cited by-同舟云学术

To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?

Published:2023-09-05 Issue:13 Volume:30 Page:8327-8334
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Farley Clara,Bassett Roland,Meric-Bernstam Funda,Bedrosian Isabelle,Caudle Abigail,DeSnyder Sarah,Hunt Kelly,Kuerer Henry,Singh Puneet,Sun Susie,Tamirisa Nina,Teshome Mediget,Hwang Rosa F.

Funder

Division of Cancer Prevention, National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-023-14245-1.pdf

Reference23 articles.

1. Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336–47. https://doi.org/10.1056/NEJMoa2108873.

2. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33. https://doi.org/10.1016/S1470-2045(10)70207-2.

3. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918–26. https://doi.org/10.1001/jama.2017.11470.